4/A//SEC Filing
Evans John M. 4/A
Accession 0000950170-25-049297
CIK 0001745999other
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 4:05 PM ET
Size
8.6 KB
Accession
0000950170-25-049297
Insider Transaction Report
Form 4/AAmended
Evans John M.
DirectorCEO
Transactions
- Exercise/Conversion
Common Stock
2025-01-30$0.67/sh+30,000$20,100→ 968,659 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-01-30−30,000→ 69,336 totalExercise: $0.67Exp: 2028-05-08→ Common Stock (30,000 underlying)
Footnotes (4)
- [F1]On February 3, 2025, the Reporting Person filed a Form 4 (the "Original Form 4") that, among other things, reported the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan. The Original Form 4 inadvertently failed to disclose the exercise of derivative securities that occurred pursuant to the same Rule 10b5-1 trading plan, which occurred immediately prior to such sale. Accordingly, this Form 4/A is being filed to disclose the omitted transaction. Immediately following the transaction reported herein, the Reporting Person directly beneficially owned 968,659 shares of common stock of Beam Therapeutics Inc.
- [F2](Continued from footnote 1) ("BEAM"), and accordingly, all disclosures of the amount of securities directly beneficially owned by the Reporting Person subsequent to the transaction reported herein and prior to the filing of this Form 4/A, including with respect to the transactions reported in the Original Form 4, should be deemed to be adjusted accordingly. As of the date the filing of this Form 4/A, the Reporting Person directly beneficially owns 938,659 shares of common stock of BEAM.
- [F3]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.
- [F4]On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,336 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.
Documents
Issuer
Beam Therapeutics Inc.
CIK 0001745999
Entity typeother
Related Parties
1- filerCIK 0001786304
Filing Metadata
- Form type
- 4/A
- Filed
- Apr 1, 8:00 PM ET
- Accepted
- Apr 2, 4:05 PM ET
- Size
- 8.6 KB